According to a recent LinkedIn post from Orasis Pharmaceuticals, the company is promoting a live educational session on presbyopia eye drops at the SECO International conference. The post points to a “myth-busting” discussion led by several optometrists with clinical experience and offers both in-person attendance and livestream access.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
The post highlights efforts to address misconceptions about presbyopia treatments and directs viewers to safety information and materials on benefits and risks via external links. For investors, this suggests an ongoing focus on physician education and market shaping, which may support adoption of the company’s presbyopia therapy over time and potentially strengthen its competitive position in the eye-care segment.